C4 Therapeutics Stock Investor Sentiment
| CCCC Stock | USD 2.46 0.11 4.68% |
About 68 percent of all C4 Therapeutics' shareholders are curious in acquiring. The analysis of the overall investor sentiment regarding C4 Therapeutics suggests that quite a large number of traders are confidant. The current market sentiment, together with C4 Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use C4 Therapeutics stock news signals to limit their universe of possible portfolio assets.
C4 Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards C4 Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of C4 Therapeutics' Stock prices. Below is the latest headlines and news related to C4 Therapeutics Stock. The global stock market is bullish. About 67% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about C4 Therapeutics that are available to investors today. This information is accessible both publicly - through C4 Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of CCCC-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of C4 Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of C4 Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to C4 Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive C4 Therapeutics alpha.
CCCC Largest EPS Surprises
Earnings surprises can significantly impact C4 Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-08 | 2024-03-31 | -0.35 | -0.41 | -0.06 | 17 | ||
2022-05-05 | 2022-03-31 | -0.58 | -0.65 | -0.07 | 12 | ||
2021-11-10 | 2021-09-30 | -0.59 | -0.51 | 0.08 | 13 | ||
2021-08-11 | 2021-06-30 | -0.59 | -0.51 | 0.08 | 13 | ||
2024-08-01 | 2024-06-30 | -0.37 | -0.26 | 0.11 | 29 | ||
2022-08-04 | 2022-06-30 | -0.69 | -0.56 | 0.13 | 18 |
There is far too much social signal, news, headlines, and media speculation about C4 Therapeutics that are available to investors today. This information is accessible both publicly - through C4 Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of CCCC-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of C4 Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of C4 Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to C4 Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive C4 Therapeutics alpha.
C4 Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Chinese Infrastructure Projects Appear on Global Currency in New Book Celebrating Belt and Road Imprint | 05/23/2025 |
2 | Acquisition by Reyno Leonard of 87100 shares of C4 Therapeutics subject to Rule 16b-3 | 06/09/2025 |
3 | Acquisition by Hoerter Steven L. of 35500 shares of C4 Therapeutics at 1.44 subject to Rule 16b-3 | 06/18/2025 |
4 | Acquisition by Grogan Donna Roy of 9609 shares of C4 Therapeutics at 1.51 subject to Rule 16b-3 | 07/01/2025 |
5 | C4 Therapeutics, Inc. Surges 27 percent Yet Its Low PS Is No Reason For Excitement | 07/11/2025 |
6 | C4 Therapeutics Inc. Stock Analysis and Forecast - Skyrocketing returns - Autocar Professional | 07/23/2025 |
7 | Ocugen Reports Q2 Loss, Misses Revenue Estimates | 08/01/2025 |
8 | CCCC Revenue Drops 46 | 08/07/2025 |
9 | FY2028 EPS Estimates for C4 Therapeutics Reduced by Analyst | 08/13/2025 |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |